OTC Markets OTCPK - Delayed Quote USD

Ginkgo Bioworks Holdings, Inc. (DNABW)

Compare
0.0091
-0.0002
(-2.15%)
At close: January 10 at 3:08:26 PM EST
Loading Chart for DNABW
DELL
  • Previous Close 0.0093
  • Open 0.0091
  • Bid 0.0082 x --
  • Ask 0.0091 x --
  • Day's Range 0.0091 - 0.0093
  • 52 Week Range 0.0091 - 0.0093
  • Volume 148,900
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

www.ginkgobioworks.com

1,218

Full Time Employees

--

Fiscal Year Ends

Recent News: DNABW

View More

Compare To: DNABW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DNABW

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -298.78%

  • Return on Assets (ttm)

    -20.92%

  • Return on Equity (ttm)

    -63.51%

  • Revenue (ttm)

    217.95M

  • Net Income Avi to Common (ttm)

    -651.19M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    616.21M

  • Total Debt/Equity (mrq)

    55.84%

  • Levered Free Cash Flow (ttm)

    -317.24M

Research Analysis: DNABW

View More

Company Insights: DNABW

Research Reports: DNABW

View More